SEC Tracker
Get the app

Oruka Therapeutics ORKA

Oruka Therapeutics reports positive trial results

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. 61% of patients in 600 mg group achieved PASI 100
  2. No serious TEAEs in 600 mg group
  3. Cash position of $1.1 billion as of June 2026
  4. Phase 3 trials planned for 2027

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Oruka Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. CytomX Therapeutics CTMX public float $372M, Jun 30, 2025
  2. Cronos Group CRON public float $380M, Jun 30, 2025
  3. REGENXBIO RGNX public float $385M, Jun 30, 2025
  4. Capricor Therapeutics CAPR public float $399M, Jun 30, 2025
  5. Cryoport CYRX public float $400M, Jun 30, 2025